Athersys Files Shelf Registration Statement to Replace Prior Shelf
March 13 2014 - 4:15PM
Athersys, Inc. (Nasdaq:ATHX) announced today that it has filed a
shelf registration statement with the U.S. Securities and Exchange
Commission ("SEC"). The new shelf registration statement will
replace a similar registration statement filed in January 2013.
Athersys currently does not have any immediate plans to offer or
sell the securities under this registration statement. As with the
prior registration statement, the replacement registration
statement is intended to provide Athersys with financial
flexibility to raise capital, over the next three years, from the
offering of up to 20,000,000 shares of common stock and/or
warrants. When declared effective, a shelf registration statement
gives a company advance regulatory approval to sell securities in
one or more separate offerings in amounts and at prices and terms
to be determined at the time of the sale.
If the securities are issued, Athersys may use the proceeds for
general corporate purposes, including, but not limited to, research
and development costs, payment obligations and capital
expenditures.
A registration statement relating to these securities has been
filed with the SEC, but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior
to the time the registration statement becomes effective. This
press release shall not constitute a solicitation of an offer to
buy, nor shall there be any sale of these securities in any state
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state. Any offer of these securities will be made solely
by means of the prospectus included in the registration statement
and any prospectus supplement that may be issued with respect to
such offering.
A copy of the prospectus included in the registration statement
may be obtained on the SEC's website at www.sec.gov. In addition,
when available, copies of the prospectus, and any prospectus
supplement relating to a particular offering, may be obtained by
contacting Athersys, Inc., attention: Laura Campbell, 3201 Carnegie
Avenue, Cleveland, Ohio 44115-2634, lcampbell@athersys.com.
About Athersys
Athersys is a clinical stage biotechnology company engaged in
the discovery and development of therapeutic product candidates
designed to extend and enhance the quality of human life. The
Company is developing its MultiStem® cell therapy product, a
patented, adult-derived "off-the-shelf" stem cell product platform
for disease indications in the cardiovascular, neurological,
inflammatory and immune disease areas. The Company currently has
several clinical stage programs involving MultiStem, including for
treating inflammatory bowel disease, ischemic stroke, damage caused
by myocardial infarction, and for the prevention of
graft-versus-host disease. Athersys has also developed a diverse
portfolio that includes other technologies and product development
opportunities, and has forged strategic partnerships and
collaborations with leading pharmaceutical and biotechnology
companies, as well as world-renowned research institutions in the
United States and Europe to further develop its platform and
products. More information is available at www.athersys.com.
The Athersys, Inc. logo is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=4548
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. These forward-looking
statements relate to, among other things, the expected timetable
for development of our product candidates, our growth strategy, and
our future financial performance, including our operations,
economic performance, financial condition, prospects, and other
future events. We have attempted to identify forward-looking
statements by using such words as "anticipates," "believes," "can,"
"continue," "could," "estimates," "expects," "intends," "may,"
"plans," "potential," "should," "suggest," "will," or other similar
expressions. These forward-looking statements are only predictions
and are largely based on our current expectations. A number of
known and unknown risks, uncertainties, and other factors could
affect the accuracy of these statements. Some of the more
significant known risks that we face that could cause actual
results to differ materially from those implied by forward-looking
statements are the risks and uncertainties inherent in the process
of discovering, developing, and commercializing products that are
safe and effective for use as human therapeutics, such as the
uncertainty regarding market acceptance of our product candidates
and our ability to generate revenues, including MultiStem for the
treatment of inflammatory bowel disease, acute myocardial
infarction, stroke and other potential indications, including
lysosomal storage disorders and the prevention of graft-versus-host
disease. These risks and uncertainties may cause our actual
results, levels of activity, performance, or achievements to differ
materially from any future results, levels of activity,
performance, or achievements expressed or implied by these
forward-looking statements. Other important factors to consider in
evaluating our forward-looking statements include: our ability to
raise additional capital; final results from our MultiStem clinical
trials; the possibility of delays in, adverse results of, and
excessive costs of the development process; our ability to
successfully initiate and complete clinical trials and obtain all
necessary regulatory approvals; changes in external market factors;
changes in our industry's overall performance; changes in our
business strategy; our ability to protect our intellectual property
portfolio; our possible inability to realize commercially valuable
discoveries in our collaborations with pharmaceutical and other
biotechnology companies; our ability to meet milestones under our
collaboration agreements; our collaborators' ability to continue to
fulfill their obligations under the terms of our collaboration
agreements; the success of our efforts to enter into new strategic
partnerships and advance our programs; our possible inability to
execute our strategy due to changes in our industry or the economy
generally; changes in productivity and reliability of suppliers;
and the success of our competitors and the emergence of new
competitors. You should not place undue reliance on forward-looking
statements contained in this press release, and we undertake no
obligation to publicly update forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACT: William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
bjlehmann@athersys.com
Investor Relations:
Lisa M. Wilson
In-Site Communications
Tel: (917) 543-9932
lwilson@insitecony.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2024 to May 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From May 2023 to May 2024